

23<sup>rd</sup> January, 2024

- |   |  |
|---|--|
| <p>(1) BSE Limited<br/>Listing Department,<br/>Phiroze Jeejeebhoy Towers,<br/>Dalal Street,<br/>Mumbai 400 001</p> <p><b>Scrip Code: 500087</b></p> | <p>(2) National Stock Exchange of India Limited<br/>Listing Department<br/>Exchange Plaza, 5<sup>th</sup> floor,<br/>Plot no. C/1, G Block,<br/>Bandra Kurla Complex,<br/>Bandra (East), Mumbai - 400 051</p> <p><b>Scrip Code: CIPLA EQ</b></p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG<br/>Societe Anonyme<br/>35A Boulevard Joseph II,<br/>L-1840 Luxembourg</p>                                |  |

**Sub: Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)**

Dear Sir/Madam,

Pursuant to Regulation 30 of the Listing Regulations, we hereby notify that Cipla (EU) Limited, UK and Cipla Holding BV, Netherlands, wholly owned subsidiaries of the Company have jointly incorporated ‘Mexicip S.A. de C.V.’, a wholly owned subsidiary in Mexico w.e.f. 22<sup>nd</sup> January, 2024.

Details required to be disclosed under the Listing Regulations, 2015 read with Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13<sup>th</sup> July 2023 have been provided in Annexure – I to this letter.

Please take the above information on record.

Yours faithfully,  
**For Cipla Limited**

**Rajendra Chopra**  
**Company Secretary**

Prepared by: Muskan Jain

**Annexure – I**

Details as per SEBI circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13<sup>th</sup> July 2023

Sr. No.	Particulars	Details
a)	Name of the target entity, details in brief such as size, turnover etc.	Mexicip S.A. de C.V. (“Mexicip”) has been incorporated as wholly owned subsidiary (“WOS”) in Mexico jointly by Cipla (EU) Limited, UK and Cipla Holding BV, Netherlands, WOS of the Company.
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	Mexicip is a related party.  None of the promoters / promoter group / group companies have any interest in Mexicip.  Arm’s length: Not Applicable
c)	Industry to which the entity being acquired belongs	Pharmaceutical Industry.
d)	Objects and impacts of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Mexicip is incorporated with an objective of sale and distribution of pharmaceutical drugs in Mexico.
e)	Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable.
f)	Indicative time-period for completion of the acquisition	Infusion of MXN 10,000 by 31 <sup>st</sup> March, 2024 or such other date as Mexicip and its shareholders deem fit.
g)	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash.
h)	Cost of acquisition and/or the price at which the shares are acquired	Subscription of 10,000 shares of MXN 1 each at par.
i)	Percentage of shareholding / control acquired and / or number of shares acquired	100%

j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years' turnover, country in which the acquired entity has presence and any other significant information (in brief)	Refer point (c) and (d). <b>Date of Incorporation:</b> 22 <sup>nd</sup> January, 2024. <b>Country:</b> Mexico. <b>Turnover:</b> Not applicable.
----	---	--